Table 1.
Baseline characteristics of participants in the Polyp Prevention Trial with genotype data by adenoma recurrence
| Baseline Characteristic | All subjects n=1723 | No recurrence n=1050 | Any recurrence n=673 | Multiple recurrence n=286 | Advanced recurrence n=109 |
|---|---|---|---|---|---|
| Age (y) | 61.0 ± 10.0 | 59.8 ± 10.2 | 62.9 ± 9.3* | 64.8 ± 9.3* | 65.6 ± 9.2* |
| Body Mass Index (kg/m2) | 27.6 ± 3.9 | 27.5 ± 3.9 | 27.7 ± 3.9 | 27.9 ± 3.8* | 28.0 ± 4.2 |
| Gender (%) | |||||
| Male | 1,103 (64.2) | 624 (59.6) | 479 (71.4)* | 215 (75.4)* | 76 (69.7) |
| Female | 615 (35.8) | 423 (40.4) | 192 (28.6) | 70 (24.6) | 33 (30.3) |
| Race (%) | |||||
| White | 1,540 (89.6) | 938 (89.6) | 602 (89.7) | 264 (92.6) | 98 (89.9) |
| African American | 135 (7.9) | 84 (8.0) | 51 (7.6) | 16 (5.6) | 11 (10.1) |
| Other | 43 (2.5) | 25 (2.4) | 18 (2.7) | 5 (1.8) | 0 |
| Education (%) | |||||
| < High school | 425 (24.7) | 252 (24.1) | 173 (25.8) | 79 (27.7) | 29 (26.6) |
| > High school | 1,293 (75.3) | 795 (75.9) | 498 (74.2) | 206 (72.3) | 80 (73.4) |
| Smoking status (%) | |||||
| Never | 683 (39.8) | 428 (40.9) | 255 (38.0) | 111 (38.9) | 42 (38.5) |
| Former | 814 (47.4) | 489 (46.7) | 325 (48.4) | 134 (47.0) | 55 (50.5) |
| Current | 221 (12.9) | 130 (12.4) | 91 (13.6) | 40 (14.0)† | 12 (11.0) |
| Family history (%) | |||||
| No | 472 (27.5) | 283 (27.0) | 189 (28.2) | 87 (30.5) | 78 (71.6) |
| Yes | 1,246 (72.5) | 764 (73.0) | 482 (71.8) | 198 (69.5)† | 31 (28.4) |
| Regular NSAID use (%)‡ | |||||
| No | 603 (50.8) | 380 (48.7) | 253 (54.1) | 108 (56.3) | 45 (58.4) |
| Yes | 582 (49.2) | 367 (51.3) | 215 (45.9) | 84 (43.7) | 32 (41.6) |
Results are presented as mean ± SD for continuous variables and as percentages for categorical variables. P values were determined by t tests and or χ2 tests, as appropriate.
*
Comparison group: no adenoma recurrence; P < 0.01.
†
Comparison group: no adenoma recurrence; P < 0.05.
‡
Regular NSAID use includes current use of NSAIDs on a regular basis (>1 per month) reported at three or more yearly study visits. The reference group of no NSAID use includes individuals who reported no current use of NSAIDs on a regular basis (<1 per month) at all five study visits.